SRC - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	PTK2	protein tyrosine kinase 2	Apoptotic cleavage of cellular proteins Regulation of actin dynamics for phagocytic cup formation Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth Signal regulatory protein family interactions EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling DCC mediated attractive signaling VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway RHO GTPases Activate WASPs and WAVEs RAF/MAP kinase cascade MET activates PTK2 signaling Extra-nuclear estrogen signaling Estrogen-dependent nuclear events downstream of ESR-membrane signaling FCGR3A-mediated phagocytosis Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	Endostatin 7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE 2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE Fostamatinib
Novel	PTK2B	protein tyrosine kinase 2 beta	Signal regulatory protein family interactions VEGFA-VEGFR2 Pathway RHOU GTPase cycle Interleukin-2 signaling	Leflunomide Genistein 4-{[4-{[(1R,2R)-2-(dimethylamino)cyclopentyl]amino}-5-(trifluoromethyl)pyrimidin-2-yl]amino}-N-methylbenzenesulfonamide Fostamatinib
Novel	PTPA	protein phosphatase 2 phosphatase activator
Novel	PTPN1	protein tyrosine phosphatase non-receptor type 1	Integrin signaling Negative regulation of MET activity Insulin receptor recycling Regulation of IFNG signaling PTK6 Down-Regulation MECP2 regulates neuronal receptors and channels Regulation of IFNA/IFNB signaling Growth hormone receptor signaling Growth hormone receptor signaling Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid, {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid Compound 19 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid 2-(Oxalyl-Amino)-Benzoic Acid {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid) Novo Nordisk a/S Compound N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid PNU177836 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid L-cysteic acid 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid -Carbonyl]-Amino}-Butyric Acid Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID ISIS 113715 Trodusquemine Ertiprotafib 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID ISOTHIAZOLIDINONE ANALOG 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid p-Benzoyl-L-phenylalanine 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
Novel	PTPN11	protein tyrosine phosphatase non-receptor type 11	Interleukin-6 signaling PI3K Cascade MAPK3 (ERK1) activation MAPK1 (ERK2) activation GPVI-mediated activation cascade Prolactin receptor signaling PIP3 activates AKT signaling Spry regulation of FGF signaling Signaling by SCF-KIT GAB1 signalosome Downstream signal transduction PECAM1 interactions Tie2 Signaling Constitutive Signaling by Aberrant PI3K in Cancer Signaling by Leptin Co-inhibition by CTLA4 Co-inhibition by PD-1 Signal regulatory protein family interactions Netrin mediated repulsion signals Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 FRS-mediated FGFR2 signaling FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Regulation of IFNG signaling RET signaling Interleukin-20 family signaling MET activates PTPN11 Regulation of RUNX1 Expression and Activity Interleukin-37 signaling Activated NTRK2 signals through FRS2 and FRS3 Interferon alpha/beta signaling Regulation of IFNA/IFNB signaling Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) FLT3 Signaling STAT5 Activation Signaling by CSF3 (G-CSF) Signaling by CSF3 (G-CSF) Signaling by CSF1 (M-CSF) in myeloid cells STAT5 activation downstream of FLT3 ITD mutants Signaling by FLT3 ITD and TKD mutants SARS-CoV-2 activates/modulates innate and adaptive immune responses Co-inhibition by BTLA	Dodecyltrimethylammonium	Metachondromatosis Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
Novel	PTPN18	protein tyrosine phosphatase non-receptor type 18	Downregulation of ERBB2 signaling Interleukin-37 signaling
Novel	PTPN2	protein tyrosine phosphatase non-receptor type 2	Negative regulation of MET activity Interleukin-37 signaling PKR-mediated signaling		Type I diabetes mellitus
Novel	PTPN21	protein tyrosine phosphatase non-receptor type 21
Novel	PTPN6	protein tyrosine phosphatase non-receptor type 6	GPVI-mediated activation cascade Regulation of KIT signaling Signaling by ALK PECAM1 interactions Co-inhibition by PD-1 Signal regulatory protein family interactions Platelet sensitization by LDL Interleukin-3, Interleukin-5 and GM-CSF signaling CD22 mediated BCR regulation Neutrophil degranulation Interferon gamma signaling Regulation of IFNG signaling Interleukin-37 signaling Interferon alpha/beta signaling Interleukin receptor SHC signaling Regulation of IFNA/IFNB signaling SARS-CoV-2 activates/modulates innate and adaptive immune responses Nuclear events stimulated by ALK signaling in cancer Growth hormone receptor signaling Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Co-inhibition by BTLA	Tiludronic acid
Novel	PTPRA	protein tyrosine phosphatase receptor type A	NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth RAF/MAP kinase cascade
Novel	PTPRC	protein tyrosine phosphatase receptor type C	Phosphorylation of CD3 and TCR zeta chains Other semaphorin interactions Neutrophil degranulation		T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
Novel	PTPRE	protein tyrosine phosphatase receptor type E		Alendronic acid Tiludronic acid
Novel	PTPRT	protein tyrosine phosphatase receptor type T
Novel	PXN	paxillin	GAB1 signalosome VEGFA-VEGFR2 Pathway Smooth Muscle Contraction Localization of the PINCH-ILK-PARVIN complex to focal adhesions Regulation of cytoskeletal remodeling and cell spreading by IPP complex components PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition
Novel	RACK1	receptor for activated C kinase 1	Regulation of TNFR1 signaling TNFR1-induced NF-kappa-B signaling pathway TNFR1-mediated ceramide production Degradation of CDH1	Copper
Novel	RAF1	Raf-1 proto-oncogene, serine/threonine kinase	Stimuli-sensing channels Rap1 signalling GP1b-IX-V activation signalling CD209 (DC-SIGN) signaling RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling IFNG signaling activates MAPKs	Sorafenib LErafAON XL281 iCo-007 Cholecystokinin Regorafenib Dabrafenib Fostamatinib
Novel	RARA	retinoic acid receptor alpha	Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Signaling by Retinoic Acid Activation of anterior HOX genes in hindbrain development during early embryogenesis Transcriptional regulation of granulopoiesis Transcriptional regulation of granulopoiesis TGFBR3 expression	Adapalene Acitretin Alitretinoin Tretinoin Tazarotene Etretinate Isotretinoin Tamibarotene LGD-1550 Trifarotene	Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate Acute myeloid leukemia (AML)
Novel	RASA1	RAS p21 protein activator 1	Downstream signal transduction EPHB-mediated forward signaling EPHB-mediated forward signaling VEGFR2 mediated cell proliferation Regulation of RAS by GAPs PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases		RASA1-related disorders, including: Parkes-Weber slndrome; Capillary malformation-arteriovenous malformation (CM-AVM); Arteriovenous fistula (AVF)
Novel	RASGRF1	Ras protein specific guanine nucleotide releasing factor 1	Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade
Novel	RET	ret proto-oncogene	RAF/MAP kinase cascade RET signaling NPAS4 regulates expression of target genes Formation of the nephric duct Formation of the ureteric bud	Sorafenib 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine Vandetanib Cabozantinib Regorafenib Ponatinib Lenvatinib Fostamatinib Amuvatinib Selpercatinib Pralsetinib	Congenital central hypoventilation syndrome (CCHS) Hirschsprung disease (HD) Thyroid cancer Renal agenesis and Renal adysplasia

Search Results for: SRC